TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26216071
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose gefitinib (500 mg/d; H group)
Study: 26216071
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose gefitinib (250 mg/d; S group)
Study: 23336248
Drug: Opicapone 5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opicapone 5, 10, 20 or 30 mg
Study: 16987384
Drug: Quinidine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine plus verapamil (Q+V) 480/240 mg/day
Study: 16987384
Drug: Quinidine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine plus verapamil (Q+V) 320/160 mg/day
Study: 1705386
Drug: Sotalol 320
Normalized name: sotalol 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol 320 mg/day
Study: 12767414
Drug: Ginkgo (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo (240 mg/d or 160 mg/d)
Study: 11037003
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg/d)
Study: 3120989
Drug: Fixed minidose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed minidose warfarin (1 mg daily for mean 20 days)
Study: 3120989
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose oral anticoagulation
Study: 3120989
Drug: Fixed minidose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed minidose warfarin
Study: 28500434
Drug: Individualized parent-child
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized parent-child treatment
Study: 26599569
Drug: Intramuscular benzathine
Normalized name: Cephapirin Benzathine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular benzathine benzylpenicillin (BPG)
Study: 23394910
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who declined the herpes zoster vaccine
Study: 26285130
Drug: Neither medication
Normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neither medication
Study: 14662276
Drug: Run-in period
Normalized name: Run Guard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Run-in period prior to randomized treatment-group assignment
Study: 9106558
Drug: Medroxyprogesterone, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medroxyprogesterone, 10 mg
Study: 24739290
Drug: No stretching
Approvals — FDA: no, EMA: no, PMDA: no
Description: No stretching treatment
Study: 19717846
Drug: Clopidogrel (300-to-600-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300-to-600-mg loading dose, 75 mg daily thereafter)
Study: 12658810
Drug: Clavulanate Potassium
Normalized name: Clavulanate Potassium
DrugBank: Clavulanic acid (DB00766)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clavulanate Potassium and Amoxicillin (1:7) dispersible tablets (Tested formulation, T)
Study: 31654294
Drug: Elagolix 150
Normalized name: elagolix 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elagolix 150 mg QD
Study: 31650182
Drug: Elagolix 200
Normalized name: elagolix 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elagolix 200 mg QD
Study: 31650182
Drug: Elagolix 300
Normalized name: elagolix 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elagolix 300 mg BID
Study: 30834932
Drug: Behavioural e‐learning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural e‐learning intervention to support nurses in managing interruptions during medication administration
Study: 19745565
Drug: Clinical dose
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical dose of nicardipine (20 mg)
Study: 1794430
Drug: Tropicamide 1%
Normalized name: TROPICAMIDE 1% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropicamide 1% in combination with phenylephrine 10%
Study: 6403956
Drug: Co-dergocrine mesylate
Normalized name: co-dergocrine mesylate
DrugBank: Ergoloid mesylate (DB01049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-dergocrine mesylate 4.5 mg once daily
Study: 22512698
Drug: Intestine without
Normalized name: pork intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intestine without olive leaf treatment
Study: 16013899
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR 150 mg daily
Study: 26976426
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg once per day
Study: 26976426
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg with pictilisib 260 mg once per day
Study: 21926153
Drug: treatment to
Normalized name: Lice Treatment Topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment to target (TT)
Study: 21926153
Drug: treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment as needed (PRN)
Study: 17111793
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (combination of topical and systemic antibiotics)
Study: 17111793
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (topical antimicrobials alone)
Study: 10814631
Drug: Cocaine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (2 mg/kg intranasally)
Study: 9121824
Drug: Treatment Helpfulness
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Helpfulness Questionnaire (THQ)
Study: 1797464
Drug: Norinyl 1+35
Normalized name: Norinyl 1+35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norinyl 1+35 (35 mcg ethinyl estradiol)
Study: 1797464
Drug: Norinyl 1+50
Normalized name: Norinyl 1+50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norinyl 1+50 (50 mcg mestranol)
Study: 29378662
Drug: ART refills
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART refills supplied 6-monthly within CARGs
Study: 29378662
Drug: ART refills
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART refills supplied 3-monthly from the health facility (control arm)
Study: 29378662
Drug: ART refills
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART refills supplied 3-monthly within CARGs
Study: 17659159
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg/day added to ongoing statin therapy
Study: 12423708
Drug: Placebo added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added to ongoing statin therapy
Study: 27671007
Drug: Postnatal additional
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postnatal additional high-dose oral vitamin A supplementation for 28 days (exact dosage not specified)
Study: 11081892
Drug: ANP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANP treatment (0.05 microg x kg(‐1) x min(‐1) for 6 hours)
Study: 11081892
Drug: No ANP
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ANP treatment (control group)
Study: 3159163
Drug: muzolimine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: muzolimine (20 mg once daily for three weeks)
Study: 3159163
Drug: nitrendipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: nitrendipine (10 mg twice daily for four weeks)
Study: 22396514
Drug: Continued AED
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued AED treatment (n = 23)
Study: 20498393
Drug: FU-based therapy
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: FU-based therapy (either FU + levamisole or FU + leucovorin)
Study: 20498393
Drug: FU-based therapy
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: FU-based therapy (in pooled data set)
Study: 11228380
Drug: QS‐21 formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: QS‐21 formulations
Study: 9052304
Drug: Lidocaine 1.5%
Normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1.5% (10 mL)
Study: 29405668
Drug: Saline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (10 mL)
Study: 9052304
Drug: Control sham
Normalized name: Dandruff Control Shampoo Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control sham (0.5 mL saline)
Study: 8300895
Drug: Sublingual estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual estradiol hydroxypropyl‐beta‐cyclodextrin (estradiol‐HP beta CD) 0.675 mg
Study: 8300895
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized estradiol 1 mg
Study: 8300895
Drug: Sublingual estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual estradiol hydroxypropyl‐beta‐cyclodextrin (estradiol‐HP beta CD)
Study: 8300895
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol hydroxypropyl‐beta‐cyclodextrin
Study: 12057715
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized estradiol
Study: 8300895
Drug: Both oral
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both oral doses (estradiol-HP beta CD and micronized estradiol)
Study: 27558901
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release oxycodone plus naloxone up to 20 mg per day
Study: 18588370
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment plus intravenous infusions of cyclophosphamide 15 mg/kg daily for two days, methylprednisolone one gram daily for three days, and mesna 15 mg/kg for four days.
Study: 10634839
Drug: Thiopental 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental 6 mg/kg
Study: 11447952
Drug: 8 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg/kg ketamine + 0.1 mg/kg diazepam
Study: 30481374
Drug: 3.75 mg/mL
Normalized name: threonine 3.75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg/mL ropivacaine infiltration followed by 2 mg/mL ropivacaine continuous wound infiltration (CWI) for 96 hours
Study: 30481374
Drug: 3.75 mg/mL
Normalized name: threonine 3.75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg/mL ropivacaine infiltration followed by 2 mg/mL ropivacaine CWI
Study: 21848574
Drug: prucalopride 2
Normalized name: prucalopride 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: prucalopride 2 mg once daily
Study: 21848574
Drug: prucalopride 10
Normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: prucalopride 10 mg once daily
Study: 21848574
Drug: placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo with 400 mg moxifloxacin on day 1
Study: 11903856
Drug: Slow-release caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release caffeine (SRC) 300 mg given twice daily (21:00 and 9:00 h) during SD
Study: 24090176
Drug: Other drug
Normalized name: Other drugs for bile therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other drug risk, family risk, and having an abnormal liver enzyme test result
Study: 19945857
Drug: PTK787/ZK222584 (PTK/ZK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTK787/ZK222584 (PTK/ZK) at a dose of 1000 mg once daily in combination with radiotherapy and temozolomide (TMZ)
Study: 19945857
Drug: PTK787/ZK222584 (PTK/ZK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTK787/ZK222584 (PTK/ZK) at a dose of 1250 mg once daily
Study: 14626338
Drug: Fluticasone propionate/salmeterol
Normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate/salmeterol combination (FSC) 100/50 or 250/50 microg twice daily
Study: 28418966
Drug: Methadone 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone 0.2 mg/kg at the start of surgery
Study: 26018333
Drug: Estradiol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol (100 µg/d)
Study: 11405325
Drug: Daily welding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily welding
Study: 2884797
Drug: Vecuronium (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (20 micrograms/kg priming dose, 60 micrograms/kg intubating dose)
Study: 2884797
Drug: Atracurium (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (100 micrograms/kg priming dose, 300 micrograms/kg intubating dose)
Study: 28770947
Drug: Anti-epileptic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-epileptic therapy with vitamin B12 (mecobalamin)
Study: 28770947
Drug: Anti-epileptic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-epileptic therapy with compound vitamin B tablets
Study: 23956857
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg of lignocaine hydrochloride
Study: 23956857
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg of dexamethasone
Study: 23956857
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of preservative-free saline
Study: 15014300
Drug: Concomitant administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant administration of Comvax, M‐M‐RII and Varivax
Study: 9850204
Drug: Sertraline (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50, 100 or 200 mg)
Study: 30649711
Drug: Metformin IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin IR crushed tablets
Study: 28762527
Drug: Eliglustat (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eliglustat (9 months initial treatment, followed by 9 months in extension)
Study: 23735473
Drug: Prasugrel 10
Normalized name: prasugrel 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 10 mg OD
Study: 21219403
Drug: Amoxicillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanic acid (amoxiclav)
Study: 16798773
Drug: bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 0.25% 0.75 ml kg(‐1) with tramadol 2 mg kg(‐1) (Group BT2)
Study: 16798773
Drug: bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 0.25% 0.75 ml kg(‐1) (Group B)
Study: 16798773
Drug: bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 0.25% 0.75 ml kg(‐1) with tramadol 1 mg kg(‐1) (Group BT1)
Study: 16798773
Drug: bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 0.25% 0.75 ml kg(‐1) with tramadol 1.5 mg kg(‐1) (Group BT1.5)
Study: 11079528
Drug: Caffeine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6 mg x kg(‐1) body mass)
Study: 11079528
Drug: Caffeine (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (9 mg x kg(‐1) body mass)
Study: 9354537
Drug: Low-dose sotalol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sotalol (80 mg twice daily)
Study: 2246915
Drug: Low-dose sotalol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sotalol
Study: 3759774
Drug: Resistive loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistive loading (33, 57, and 73 cm H2O X l‐1 X s) during exercise tests
Study: 17715033
Drug: Periodic tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodic tamoxifen treatment
Study: 17715033
Drug: Consecutive tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consecutive tamoxifen treatment
Study: 8157768
Drug: Flurbiprofen (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (100 mg daily)
Study: 3046405
Drug: Extracts composed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extracts composed of any combination of alder, birch and hazel pollen (Group 1 (ABC))
Study: 26591200
Drug: combined preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: combined preparation (fenoterol/ipratropium bromide)
Study: 23747795
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) delivery of indocyanine green (ICG)
Study: 21627558
Drug: Risedronate 35
Normalized name: risedronate 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 35 mg once a week and calcium with vitamin D
Study: 20180356
Drug: Risedronate 35
Normalized name: risedronate 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 35 mg once a week
Study: 12679710
Drug: Nutritional status
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional status improvement and treatment of parasitic infections
Study: 8440759
Drug: Methylprednisolone (20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (20, 50, 80 mg)
Study: 8440759
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide (20, 50, 80 mg)
Study: 8440759
Drug: Dexamethasone (20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (20, 50, 80 mg)
Study: 4063010
Drug: Veterans Administration
Normalized name: benzalkonium chloride Topical Foam [Veteran Shield 24]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veterans Administration nursing care units
Study: 27866182
Drug: Homeopathic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic treatment (9 drugs including Pulsatilla nigricans, Sepia succus, Lycopodium clavatum, sulphur, Lachesis trigonocephalus, Nux vomica, Calcarea carbonica, phosphorus, Conium maculatum) administered as 6 drops orally 2 times per day for 4 consecutive days each week, with a 3-day interval between doses.
Study: 1444292
Drug: Cefotaxime, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime, 2 g intravenously at 6‐h intervals during surgery and then at 8‐h intervals thereafter for 48 h
Study: 1444292
Drug: Ampicillin, 2
Normalized name: Ampicillin, 250 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin, 2 g intravenously at the same dose and schedule as cefotaxime
Study: 1444292
Drug: Systemic antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibiotics plus a 3‐week regimen of oral nonabsorbable antibiotics (gentamicin, polymyxin E, and nystatin)
Study: 8403669
Drug: Systemic antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibiotics alone
Study: 18708988
Drug: Intraarticular lumbar
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraarticular lumbar facet joint injections with lidocaine and triamcinolone
Study: 12209099
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg/d for 6 weeks
Study: 1763561
Drug: Misoprostol (MS)
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol (MS) therapy
Study: 6433840
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose urokinase (UKl)
Study: 6433840
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose urokinase (UKh)
Study: 29630134
Drug: Voriconazole sequential
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Voriconazole sequential therapy
Study: 27292585
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy every 2 weeks for 15 weeks
Study: 27292585
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment every 2 weeks for 15 weeks
Study: 12891248
Drug: Fluvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (40 mg/day)
Study: 2004805
Drug: Diltiazem (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (90 mg/day)
Study: 24256699
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fluvastatin (40 mg/day) and diltiazem (90 mg/day)
Study: 22479786
Drug: Water-only preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water-only preparation
Study: 15574070
Drug: KLIP program
Approvals — FDA: no, EMA: no, PMDA: no
Description: KLIP program (knee ligament injury prevention program), low-intensity plyometric exercises, 9 weeks duration, twice a week
Study: 1489073
Drug: Magnesium aspartate
Normalized name: Magnesium aspartate
DrugBank: Magnesium aspartate hydrochloride (DB16619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium aspartate infusion (0.8 mEq/kg per h for 15 min, then reduced to 0.2 mEq/kg per h until aortic cannulation)
Study: 17694684
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no magnesium infusion)
Study: 1489073
Drug: Magnesium aspartate
Normalized name: Magnesium aspartate
DrugBank: Magnesium aspartate hydrochloride (DB16619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium aspartate infusion
Study: 28659614
Drug: Transcranial static
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial static magnetic field stimulation (tSMS) ON medication.
Study: 21385988
Drug: Rolapitant 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rolapitant 20 mg
Study: 21385988
Drug: Rolapitant 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rolapitant 70 mg
Study: 9014006
Drug: Inactivated combined
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated combined vaccine (ICV) against Q fever
Study: 1547611
Drug: Bi-annual topical
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bi-annual topical APF gel applications
Study: 2860494
Drug: Tri-potassium di-citrato
Normalized name: di-isopropylammonium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tri-potassium di-citrato bismuthate (TDB) tablet four times a day
Study: 28801122
Drug: Serum deoxycholic
Normalized name: deoxycholate
DrugBank: Deoxycholic acid (DB03619)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Serum deoxycholic acid concentration > 58ng/mL